Values First Advisors Inc. Buys 5,090 Shares of Exscientia plc (NASDAQ:EXAI)

Values First Advisors Inc. increased its stake in Exscientia plc (NASDAQ:EXAI) by 10.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 55,958 shares of the company’s stock after acquiring an additional 5,090 shares during the period. Values First Advisors Inc.’s holdings in Exscientia were worth $359,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of EXAI. Tower Research Capital LLC TRC grew its holdings in shares of Exscientia by 101.3% during the 3rd quarter. Tower Research Capital LLC TRC now owns 5,808 shares of the company’s stock worth $26,000 after acquiring an additional 2,923 shares during the period. Bank of America Corp DE grew its holdings in shares of Exscientia by 65.5% during the 4th quarter. Bank of America Corp DE now owns 5,092 shares of the company’s stock worth $27,000 after acquiring an additional 2,015 shares during the period. UBS Group AG grew its stake in shares of Exscientia by 2,269.3% in the 4th quarter. UBS Group AG now owns 7,108 shares of the company’s stock worth $38,000 after buying an additional 6,808 shares during the last quarter. Rathbones Group PLC bought a new position in Exscientia during the 3rd quarter valued at approximately $47,000. Finally, Tocqueville Asset Management L.P. bought a new stake in Exscientia in the third quarter worth $58,000. Institutional investors own 41.58% of the company’s stock.

Analysts Set New Price Targets

Separately, Bank of America cut shares of Exscientia from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $11.00 to $9.00 in a research note on Friday, January 5th.

Exscientia Price Performance

NASDAQ:EXAI traded down $0.06 during mid-day trading on Thursday, reaching $5.72. The company’s stock had a trading volume of 504,352 shares, compared to its average volume of 749,451. Exscientia plc has a 12-month low of $4.17 and a 12-month high of $9.12. The firm’s fifty day moving average price is $6.20 and its two-hundred day moving average price is $5.86. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.22 and a quick ratio of 6.22.

Exscientia Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.